Login to Your Account



Dark Horse Fovista Challenges Regeneron's Eylea in Wet AMD

By Catherine Shaffer
Staff Writer

Thursday, June 14, 2012
Stellar Phase IIb results reported by Ophthotech Corp. for Fovista have harshed Regeneron Pharmaceuticals Inc.'s mellow just six weeks after the highly successful launch of competing product Eylea (aflibercept opthalmic solution).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription